id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-277117-11m27kmi	Khialani, Bharat	Transcatheter management of severe aortic stenosis during the COVID-19 pandemic	2020-06-10		.txt	text/plain	4660	241	46	With the primary goal of reducing the risk of spread of COVID-19, protecting patients and healthcare teams and preserving access to necessary/emergency care, the UK National Health Service (NHS) issued specialty guidance for the management of cardiology patients during this time. 4 While surgical valve replacement (sAVR) was the treatment of choice for decades, transcatheter aortic valve implantation (TAVI) has become an increasingly safe and effective treatment option in patients at high or intermediate risk. 26 The PARTNER 2A trial, which randomised 2032 patients with intermediate surgical risk (Society of Thoracic Surgery Predicted risk of Mortality (STS-PROM) score 4%-8% and Heart Team consensus) to either TAVI or sAVR, demonstrated equivalent outcomes at 2 years. ► Transcatheter aortic valve implantation (TAVI) is an effective treatment for AS and has less impact on hospital (and particularly critical care) capacity than surgical AVR. Transcatheter versus surgical aortic valve replacement in patients with severe aortic stenosis at low and intermediate risk: systematic review and metaanalysis	./cache/cord-277117-11m27kmi.txt	./txt/cord-277117-11m27kmi.txt